Jawed K,Nisar N,Hussain M,Nawab F M .2019 .A study based on use of Complementary and Alternative Medicine among Diabetic Patients in Karachi, Pakistan. J Dow Univ Health Sci, : 1310-6.
Basit A,Fawwad A,Abdul Basit K,Waris N,Tahir B,Siddiqui IA .2020 .Glycated hemoglobin (HbA1c) as diagnostic criteria for diabetes: the optimal cut-off points values for the Pakistani population; a study from second National Diabetes Survey of Pakistan (NDSP). BMJ Open Diabetes Res Care, 8 : 1058.
Almetwazi M,Alwhaibi M,Balkhi B,Almohaini H,Alturki H,Alhawassi T .2019 .Factors associated with glycemic control in type 2 diabetic patients in Saudi Arabia. Saudi Pharm J, 27 : 384-8.
Dharmeshkumar DP,Patel NM,Savadi RV,Akki KS .2008 .Mruthunjaya K. Alleviation of alloxan-induced diabetes and its complications in rats by Actinodaphnehookeri leaf extract. Bangladesh J. Pharmacol, 3 : 102-6.
Garber AJ,Abrahamson MJ,Barzilay JI,Blonde L,Bloomgarden ZT,Bush MA .2016 .Consensus Statement by The American Association of Clinical Endocrinologists and American College of Endocrinology on The Comprehensive Type 2 Diabetes Management Algorithm--2016 Executive Summary. Endocr Pract, 22 : 84-113.
Mehmood R,Khan M,Jawed I,Mahmood I .2011 .Comparison of Efficacy and Safety Profile of Gabapentin and Carbamazepine in Painful Diabetic Neuropathy. J Dow Univ Health Sci, 5 : 55-9.
Kalra S,Atkin S,Cervera A,Das AK,Demir O. Multinational AK .2018 .Consensus: Insulin Initiation with Insulin Degludec/As part (IDegAsp). Adv Ther, 35 : 928-36.
Hanefeld M,Fleischmann H,Siegmund T,Seufert J .2020 .Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020. Update. Diabetes Ther, 11 : 1645-66.
Cho KY,Nakamura A,Oba-Yamamoto C,Tsuchida K,Yanagiya S K .2020 .Switching to Once Daily Insulin Degludec/ Insulin As part from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. Diabetes Metab J, 44 : 532-41.
Mehta R,Chen R,Hirose T,John M,Kok A .2020 .Practical use of insulin degludec/insulin as part in a multinational setting: beyond the guidelines. Diabetes Obes Metab, 22 : 1961-75.
Haahr H,Fita EG,T. EG .2017 .A Review of Insulin Degludec/Insulin As part: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Clin Pharmacokinet, 56 : 339-54.
Hirose T,Awata T,Yamamoto Y,Hemmingsen MP. .2018 .Clinical considerations for use of insulin degludec/insulin as part in Japanese patients. Expert Opin Biol Ther, 18 : 77-85.
Özçelik S,Çelik M,Vural A,Aydın B,Özçelik M. .2020 .Outcomes of transition from premixed and intensive insulin therapies to insulin as part/degludec coformulation in type 2 diabetes mellitus: a real-world experience. Arch Med Sci, 17 : 1-8.
Yang W,Ma J,Hong T.,Efficacy T. .2019 .and safety of insulin degludec/insulin as part versus biphasic insulin as part 30 in Chinese adults with type 2 diabetes: A phase III, openlabel, 2:1 randomized, treat-to-target trial. Diabetes Obes Metab, 21 : 1652-60.
Demir T,Turan S,Unluhizarci K,Topaloglu O,Tukek T .2021 .Use of Insulin Degludec/Insulin As part in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns. Front Endocrinol, 12 : 616514.
Moon S,Chung HS,Kim Y,Yu JM,Jeong WJ JM .2021 .Efficacy and Safety of Insulin Degludec/Insulin As part Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis. Metabolites, 11 : 639.